Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

PURPOSE Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and 23 aCML). The primary end point was overall hematologic response rate (ORR) by the end of 6 continuous 28-day cycles for the first 25 patients enrolled. We considered a response as either partial (PR) or complete response (CR). We expanded accrual to 44 patients to increase our ability to evaluate secondary end points, including grade ≥ 3 adverse events, spleen volume, symptom assessment, genetic correlates of response, and 2-year survival. RESULTS ORR was 32% for the first 25 enrolled patients (8 PR [7 CNL and 1 aCML]). In the larger cohort of 44 patients, 35% had a response (11 PR [9 CNL and 2 aCML] and 4 CR [CNL]), and 50% had oncogenic CSF3R mutations. The mean absolute allele burden reduction of CSF3R-T618I after 6 cycles was greatest in the CR group, compared with the PR and no response groups. The most common cause of death is due to disease progression. Grade ≥ 3 anemia and thrombocytopenia were observed in 34% and 14% of patients, respectively. No serious adverse events attributed to ruxolitinib were observed. CONCLUSION Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.

[1]  M. Brancaccio,et al.  Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia , 2018, Molecular Cancer.

[2]  A. Tefferi,et al.  CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival , 2018, Blood Cancer Journal.

[3]  Snigdha Sarkar,et al.  Splenic Volume: Correlation between Ultrasonogram and Standard CT Measurements , 2018 .

[4]  J. Tyner,et al.  Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia , 2017, Current Hematologic Malignancy Reports.

[5]  N. Cross,et al.  Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia , 2017, Haematologica.

[6]  E. Purev,et al.  Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib , 2017, Haematologica.

[7]  Li-Hong Shou,et al.  Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis , 2017, PloS one.

[8]  K. Komurov,et al.  Enhanced MAPK signaling is essential for CSF3R induced leukemia , 2016, Leukemia.

[9]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[10]  A. Tefferi,et al.  Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management , 2016, American journal of hematology.

[11]  G. Wertheim,et al.  Atypical Chronic Myeloid Leukemia in Two Pediatric Patients , 2016, Pediatric blood & cancer.

[12]  B. Druker,et al.  Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia , 2015, Cureus.

[13]  Emily A. Stevens,et al.  The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I , 2015, Clinical Cancer Research.

[14]  Francisco Cervantes,et al.  A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis , 2015, Haematologica.

[15]  D. Badran,et al.  Ultrasonographic assessment of splenic volume and its correlation with body parameters in a Jordanian population , 2015, Saudi medical journal.

[16]  M. Cazzola,et al.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. , 2015, Blood.

[17]  V. Devita,et al.  DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology , 2015 .

[18]  B. Druker,et al.  Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia , 2014, Leukemia research reports.

[19]  F. Stingo,et al.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. , 2014, Blood.

[20]  A. Kohlmann,et al.  Postallogeneic monitoring with molecular markers detected by pretransplant next‐generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms , 2014, European journal of haematology.

[21]  B. Druker,et al.  Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization* , 2014, The Journal of Biological Chemistry.

[22]  T. Barbui,et al.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.

[23]  Angela G. Fleischman,et al.  The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. , 2013, Blood.

[24]  M. Heuser,et al.  SETBP1 mutation analysis in 944 patients with MDS and AML , 2013, Leukemia.

[25]  Je-Hwan Lee,et al.  Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms , 2013, Blood research.

[26]  S. Miyano,et al.  Somatic SETBP1 mutations in myeloid malignancies , 2013, Nature Genetics.

[27]  Angela G. Fleischman,et al.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. , 2013, The New England journal of medicine.

[28]  J. Tyner,et al.  CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia , 2013, Leukemia.

[29]  R. Laborde,et al.  SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML , 2013, Leukemia.

[30]  D. Birnbaum,et al.  SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias , 2013, Leukemia.

[31]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[32]  T. Barbui,et al.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.

[33]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[34]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[35]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[36]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[37]  F. Mandelli,et al.  Identification of risk factors in atypical chronic myeloid leukemia. , 2006, Haematologica.

[38]  A. Tefferi,et al.  WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature , 2005, Leukemia.

[39]  A. Elmaagacli,et al.  Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia , 2004, Bone Marrow Transplantation.

[40]  I. Touw,et al.  Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. , 2004, Blood.

[41]  B. Löwenberg,et al.  Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. , 1998, Blood.

[42]  P. Jacobsen.  Design and analysis of clinical trials. , 1988, Journal of dentistry.